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Adriamycin-associated nephropathy (AAN) remains
poorly understood. We hypothesized that adriamycin
affects endothelial progenitor cells (EPCs), leading to
impaired regeneration. We analyzed renal hemato-
poietic stem cells (HSCs) and EPCs in mice with AAN
and examined the potential contribution of adoptive
transfer of intact EPCs to the repair processes. FACS
analyses revealed that populations of HSCs and EPCs
were scarcely represented in control kidneys and did
not change numerically in kidneys obtained from
mice with AAN. The observed defect in engraftment
was attributable to the decreased viability and in-
creased senescence of EPCs. Adoptive transfer of in-
tact EPCs improved proteinuria and renal function,
with a threefold decrease in mortality. Infusion of
EPCs to adriamycin-treated mice reduced plasma lev-
els of interleukin-1 and - and granulocyte-colony
stimulating factor as well as increased the level of
vascular endothelial growth factor with concomitant
improvement of vascular density and reduction of
apoptosis. An additional mechanism of tissue repair
is proposed based on tunneling nanotube formation
between EPCs and endothelial cells exposed to adria-
mycin, leading to the multiple rounds of exchange
between EPCs and mature cells. In conclusion, AAN is
associated with development of EPC incompetence;
adoptive transfer of intact EPCs blunts morphological
and functional manifestations of AAN; and the pro-
posed mechanisms of repair by EPCs include direct
incorporation into blood vessels, paracrine signaling,
and tunneling nanotube renewal of mitochondrial pool
in endothelial cells. (Am J Pathol 2010, 176:1685–1695;
DOI: 10.2353/ajpath.2010.091071)
Molecular pharmacology profile of anthracycline antibi-
otic Adriamycin (Doxorubicin) includes inhibition of nu-
cleic acid synthesis and cytochrome c oxidase, interca-
lation of DNA, and generation of reactive oxygen species,
which account not only for its oncolytic effects but also for
the depression of the bone marrow and development of
cardiomyopathy and nephropathy.1–3 While cardiotoxicity is
a major limiting factor in the use of this chemotherapeutic
agent, adriamycin-associated nephropathy (AAN) con-
tributes significantly to its toxicologic profile. Toxicity of
anthracyclines in general is poorly understood.2 AAN
has been variably attributed to complement activation,
increased production of reactive oxygen species, re-
duction in heparan sulfate and increased heparanase
expression in glomeruli, and dysregulation of renin-an-
giotensin system,4,5 as well as activation of p38 MAP
kinase and TGF-beta1/Smad signaling,6 among other
proposed mechanisms. It is instructive that the kidney-
resident side population cells, capable of multilineage
differentiation, as well as the main population cells (de-
void of side-population cells) adoptively transferred to
mice with AAN resulted in the reduction of proteinuria.7
These studies raised a legitimate question whether adria-
mycin affects not only the bone marrow hematopoietic
stem cells (HSCs), but also bone marrow–derived and
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renal-resident stem and/or endothelial progenitor cells
and whether this injury may provide explanation for the
progressive nature of AAN. Here, we analyzed quantita-
tively and qualitatively stem and endothelial progenitor
cells, (consensually characterized as HSCs based on the
co-expression of surface markers CD150 and CD117
c-Kit or endothelial progenitor cells EPCs based on
the co-expression of surface markers CD34 and Flk-1
with or without CD45 expression) present in the kidneys
of mice with AAN and examined the potential contribution
of adoptive transfer of intact endothelial progenitor cells
to the repair processes.
Materials and Methods
Animals and Induction of AAN
All animal protocols were conducted in accord with the
National Institutes of Health guidelines and were ap-
proved by the Institutional Animal Care Committee. Male
8- to 12-week-old BALB/c mice (Jackson Labs, Bar Har-
bor, ME) were housed under 12-hour light:dark cycle, fed
a regular chow, and received water ad lib. Animals re-
ceived tail vein injection of 10.2 mg/kg adriamycin to
induce AAN. An additional group of mice was treated
with EPCs by adoptive transfer of approximately 5  105
cultured EPCs injected into the circulation via the tail vein
on the day 5 postadriamycin. Nontreated mice received
an injection of normal saline. On days 0, 4, and 10 and at
2 and 3 weeks, mice were placed in metabolic cages for
24-hour urine collection. Mice were sacrificed at 3 weeks
after adriamycin injection. On the day of sacrifice, after
Ketamin/Xylazine anesthesia, blood was obtained through
left ventricular puncture and animals were perfused with
normal saline followed by perfusion-fixation with 4% para-
formaldehyde for morphological studies. Alternatively, fixa-
tion step was omitted and mice were used for stem cell
isolation, as detailed below.
Cell Isolation from the Kidney and FACS
Analysis
For stem cell isolation, single-cell suspension was pre-
pared from the whole kidney. Kidneys from each exper-
imental group were placed in 2 ml of ice-cold RPMI 1640
(Invitrogen, Carlsbad, CA) and minced using a sterile
scalpel. Digestion of the tissue was performed in colla-
genase II (Invitrogen) solution (1 mg/ml of RPMI 1640)
for 30 minutes at 37°C in 5% CO2. Cell suspensions
were passed through a 35-m nylon sieve. Repeated
digestions were performed until microscopic evalua-
tion showed a suspension of single cells. Finally, cells
were washed in PBS-BSA 1% (w/v), counted, and kept
on ice in the dark.
FACS analysis was performed to quantify the dynam-
ics of EPCs and HSCs in AAN model. For this analysis,
1  106 cells from the single-cell suspensions were in-
cubated with specified primary antibodies for 1 hour at
4°C in the dark. The following antibodies were used for
incubation: FITC-conjugated anti-mouse CD34, PE-con-
jugated anti-mouse Flk-1, PE-conjugated anti-mouse
CD150, FITC-conjugated anti-mouse CD117 (c-Kit; BD
Pharmingen, San Diego, CA). After each incubation step,
cells were washed with PBS-BSA 1% (w/v) and finally
fixed in 1% paraformaldehyde. Data were acquired using
a FACScan cytometer equipped with a 488-nm argon
laser and a 635-nm red diode laser and analyzed using
CellQuest software (Becton Dickinson, Franklin Lakes,
NJ). The set-up of FACScan was performed using un-
stained cells. For quantification of EPCs and HSCs, the
number of CD34/Flk-1 and CD150/c-Kit double-positive
cells within the monocytic cell population was counted.
Preparation of EPCs and Cell Culture
To isolate bone marrow mononuclear cells, cells were
obtained by flushing the tibias and femurs of BALB/c
mice with PBS and density gradient centrifugation with
Histopaque-1077 (Sigma Chemical Co., St. Louis, MO)
was performed. Bone marrow mononuclear cells were
cultured in Mouse Endothelial Progenitor Cell Culture
Serum-Free Media (Celprogen, San Pedro, CA) on dishes
coated with 10 g/ml pronectin (Sigma, St Louis, MO).
After 3 days in culture, nonadherent cells were removed,
and medium exchanged every 2 days. Thus prepared
cells were further characterized to ensure the purity of
EPC population (95% of cells are labeled by these
markers) by (1) uptake of DiI-labeled acetylated low-
density lipoprotein (2.4 g/ml of Dil-Actylated-LDL, Bio-
medical Technologies, Inc., Stoughton, MA), and (2) Lec-
tin binding (25 g/ml of Fluorescein-Ulex Europeus Lectin,
Biomeda Corp., Forster City, CA). Colony-forming unit
assay was performed according to the previously de-
scribed protocol.8 Briefly, 1  105 bone marrow mono-
nuclear cells were plated on pronectin-coated dishes
and 2 weeks later colonies (50 cells) were counted.
Cells were also stained for the expression of CD31. In
some in vitro experiments, mouse embryonic EPCs, pre-
viously established and characterized,9 were used.
To detect apoptotic and necrotic cells, FACS analysis
using fluorescein isothiocyanate-Val-Ala-Asp (OMe)-flu-
oromethylketone (FITC-VAD-FMK, Calbiochem, La Jolla,
CA) and 7-Aminoactinomycin D (7-AAD, Invitrogen) was
performed. Detection of cell senescence was accom-
plished by staining for senescence-associated  galac-
tosidase (SA--gal).
Morphological Analyses
Kidneys were collected from mice at 3 weeks after adria-
mycin injection for morphological analysis. Midcoronal
kidney sections were fixed in 4% paraformaldehyde and
embedded in paraffin. Paraffin sections (4 m thick) were
stained with hematoxylin and eosin, periodic acid-Schiff,
and Masson trichrome and examined by a nephro-
pathologist blinded to the origin of individual prepara-
tions. Semiquantitative grading of injury, designed to
evaluate the degree of glomerular injury (segmental scle-
rosis, podocyte hypertrophy, and proliferation) and tubu-
lointerstitial injury (tubular casts, debris, necrosis, and
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interstitial fibrosis), was used. The degree of injury and
fibrosis score ranging from 0 to 3 was determined as
follows: 0, normal kidney; 1, mild changes; 2, moderate
changes; 3, severe changes. The scores were deter-
mined in each section selected at random, and 20
fields were examined under 100 magnification. Data
are presented as a sum of individual pathological scores,
each obtained in 5 different mice.
For immunohistochemical detection of renal vascula-
ture, cryosections were stained with endothelial-specific
antibodies – CD31 (BD Phermingen, San Diego, CA) and
von Willebrand factor (Dako, Glostrup, Denmark). Termi-
nal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) staining kit (Calbiochem FragEL
DNA Fragmentation Detection Kit, La Jolla, CA) was used
to detect apoptotic cells in paraffin sections, according to
manufacturer’s instructions.
Multiplex Analysis of Cyto- and Chemokines
Profiling of cyto- and chemokines and vascular endothe-
lial growth factor (VEGF) release was accomplished us-
ing multiplex analysis of the plasma obtained from exper-
imental animals (Luminex Inc, Austin TX). The following
parameters were determined: interleukin (IL)-1, IL-1,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p70), IL-13,
IL-15, IL-17, interferon-, interferon-–inducible protein
(IP-10), granulocyte-colony stimulating factor (G-CSF),
granulocyte-macrophage-colony stimulating factor, tumor
necrosis factor-, keratinocyte chemoattractant (KC),
monocyte chemoattractant protein, macrophage inflamma-
tory protein, and regulated on activation normal T cell
expressed and secreted (RANTES) as previously de-
tailed by us.10 The plates were analyzed using Luminex
IS100 analyzer. The data were saved and evaluated as
median fluorescence intensity using appropriate curve-
fitting software (Luminex 100IS software version 2.3). A
5-parameter logistic method with weighting will be used,
as a part of the software routine.
For measurement of plasma VEGF, we used ELISA
Development kit (Peprotech, Rocky Hill, NJ) with 96-well
ELISA microplates (Nunc MaxiSorp, Rochester, NY) and
2,2-azinobis-(3-ethyl-benzothiazoline-6-sulfonic acid;
Sigma, St Louis, MO).
Analytical Protocols
Urine albumin content was determined with a Bio-Rad
Protein Assay with BSA standards (Bio-Rad, Hercules,
CA), and urine and serum creatinine were determined
with a Creatinine Assay kit (Cayman Chemical, Ann Ar-
bor, MI). Proteinuria was expressed as urine protein/
creatinine ratio.
EPC Labeling and Tracing in AAN Model
To track injected EPCs in the tissues after engraftment,
cells were labeled with carboxyfluorescein diacetete suc-
cinimidyl ester (CFDA SE, Invitrogen, Carlsbad, CA). For
this purpose, EPCs were washed once with PBS and
resuspended in 10 mol/L CFDA SE/PBS for 15 minutes
at 37°C. After labeling, the cells were washed twice in
PBS, and injected via the tail vein. To examine their
incorporation, the kidneys were removed on day 21, and
costained with CD31 monoclonal antibody (BD Phermin-
gen), followed by Alexa fluor–labeled antibodies against
rat IgG (Invitrogen, Carlsbad, CA).
Statistical Analysis
Statistical analysis was performed using software pro-
gram, GraphPad Prism 4 (Software Inc, San Diego, CA).
For survival analysis, percent survival was analyzed us-
ing Kaplan–Meier method. The statistical significance of
the survival experiments was determined using the log-
rank test. Non-normally distributed data were analyzed
by nonparametric Mann–Whitney U test. Multiple group
comparisons were performed using one-way or two-way
analysis of variance with post hoc Bonferroni correction.
Values of P  0.05 were considered statistically signifi-
cant. All values are expressed as mean  SEM.
Results
The Fate of Renal Stem/Progenitor Cells in AAN
Mice developed progressive elevation of serum creati-
nine and worsening proteinuria after adriamycin injection
and exhibited an increased mortality rate, as illustrated
by Kaplan–Meier survival curve (Figure 1, A–C).
Morphological analysis of kidneys obtained from adri-
amycin-injected mice revealed focal podocyte proliferation
with epithelial-to-fibroepithelial adhesions to the Bowman
capsule, frequent podocytic hypertrophy with occasional
vacuolization, and rare segmental sclerosis. Glomeruli
appeared slightly swollen with mild-to-moderate (1 to 2)
endocapillary and podocytic hypertrophy and with Bow-
man spaces focally containing proteinaceous material.
Tubules were frequently dilated, contained variable num-
bers of hyaline casts, and showed widespread degener-
ation and focal epithelial necrosis (Figure 2, A and B).
The population of CD34Flk-1 cells (approximately
50% of these cells did not express CD45 and presumed
to be EPCs) harvested from the kidney equaled 0.04% of
the total cellular endowment in control mice and showed
a modest elevation on day 14 postinjection of adriamycin
(0.087%; Figure 3A). However, at day 21 of AAN the
population of EPCs in the kidney was indistinguishable
from the baseline (Figure 3B). FACS analyses of different
subsets of stem and progenitor cells revealed that the
population of HSCs (c-Kit/CD150) was represented in
control kidneys by 0.043% of total cell number. This
population did not change numerically in kidneys ob-
tained from mice with AAN (Figure 3C), averaging on day
14 postinjection 0.073% and on day 21 0.02%.
The observed lack of an expected surge of stem/
progenitor cells engrafting the AAN kidneys could not
be attributed to the loss of the stromal cell–derived fac-
tor-1 (SDF-1) production, because immunohistochemical
staining of the kidneys showed its enhanced expression
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in the cortical and medullary areas (Figure 4A). In con-
trast to this, the clonogenicity of EPCs was perturbed:
colony-forming unit assay using EPCs obtained from
mice receiving adriamycin showed a significant suppres-
sion of this function compared with control (Figure 4B),
suggesting that the adriamycin-induced functional in-
competence of EPCs may participate in the defective
engraftment and, consequently, impaired regenerative
capacity.
To address the cause(s) of functional incompetence,
we examined in vitro the viability of EPCs after adriamycin
administration. The rate of apoptosis (detected by FACS
analysis using FITC-VAD-FMK) in cultured EPCs treated
with various doses of adriamycin was increased already
at the concentration of 1 mol/L, whereas necrosis (as
judged by FACS analysis of 7-AAD staining) was detect-
able at 10 mol/L adriamycin (Figure 5A). EPCs treated
with adriamycin also showed signs of stress-induced
premature senescence, as judged by the results of stain-
ing for senescence-associated -galactosidase (Figure
5B). Collectively, these findings suggested that EPCs are
targeted by this anthracyclin antibiotic to limit their viabil-
ity or develop cell cycle arrest, thus explaining in part the
results of colony forming unit assay.
Adoptive Transfer of EPCs to Mice with AAN
To gain further insights into the possibility of the failed
EPC-induced regeneration in adriamycin nephropathy, in
the next series of experiments mice received transfusion
of EPCs obtained from healthy age- and gender-matched
BALB/c donors. EPCs were isolated, maintained, and
expanded as detailed in the Methods. Mice received
injection of approximately 5  105 cells on day 5 after
adriamycin injection, at the time when no significant pro-
teinuria was yet detectable. This protocol resulted in a
dramatic improvement in proteinuria and a moderate but
significant improvement of renal function, as judged by
the serum creatinine, 2 to 3 weeks postinitiation of AAN
(Figure 1, A and B). Moreover, the overall mortality was
decreased almost threefold by 3 weeks (Figure 1C).
Morphological studies of the kidneys obtained from
mice that received adriamycin followed by EPC infusion
revealed no focal segmental glomerulosclerotic lesions
and marked attenuation of podocytic hypertrophy, vacu-
olization, and proliferation. Glomerular and cellular swell-
ing was also attenuated (0.5 to 1.5) compared with
mice that did not receive EPCs. Rare finding of protein in
the Bowman’s space was present. Tubular damage was
markedly reduced (Figure 2, A and B).
A single systemic injection of EPCs was accompanied
by a dramatic increase in HSCs and EPCs in the affected
kidneys (Figure 3, B and C). The population of HSCs,
which was not changed in the kidneys of adriamycin-
injected mice, was dramatically enriched (more than sev-
enfold) in mice receiving EPC transplantation. This latter
group also showed elevation in HSCs in the spleen and
bone marrow, reaching the level found in untreated ani-
mals (not shown). EPCs in the kidneys of adriamycin-
treated mice receiving cell therapy showed a progressive
increase, whereas increase was maximal on day 14 in the
spleen and day 21 in the bone marrow, perhaps reflect-
ing the trafficking of these cells from the bone marrow to
the spleen and the kidney (not shown).
Sites of Engraftment of EPCs and Potential
Mechanisms of Repair
The injected CFDA-tagged EPCs engrafting the kidney
were detectable mostly in the cortical and medullary
microvasculature (Figure 6A). In the cortex, EPCs were
frequently observed in the glomeruli and peritubular cap-
illaries and rarely in the tubules. In the medulla, EPCs
were detectable in the vasae rectae, as judged by the
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Figure 1. Renal function and survival of mice treated with adriamycin.
Circles indicate control; squares, adriamycin; triangles, adriamycin fol-
lowed by adoptive transfer of EPCs. Arrows indicate the time of infusion of
adriamycin and EPCs. A: Urine protein:creatinine ratio. B: Serum creatinine
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versus adriamycin, Logrank test: P  0.05.
1688 Yasuda et al
AJP April 2010, Vol. 176, No. 4
co-localization of transplanted cells with CD31-stained
cells. The approximate number of EPCs engrafting the
kidney in AAN was quantified by integrating the number
of cells per section to the entire kidney volume. For this
purpose, kidney volume was approximated by ellipse
volume, according to the equation: volume 	 4/3abc,
where a, b, and c are the axes. The proportion of EPCs
that engrafted kidneys and was detectable 2 and 3
weeks after their transplantation (Figure 6B) was limited
to 1% to 2% of the number of injected cells. The scarcity
of injected EPCs in the kidneys raised the question
whether and how these minute numbers of progenitors
could be responsible for the observed marked attenua-
tion of AAN. To address this problem, we considered the
possibility of (1) paracrine signaling by adoptively trans-
ferred EPCs and (2) their participation in a recently de-
scribed novel mechanism of cell-to-cell communication
via the tunneling nanotubes (TNT).11
First, we examined the possibility that adoptively trans-
ferred EPCs can change the cytokine profile via a para-
crine mechanism, as advocated by many investigators
(reviewed by Gnecchi et al12). Multiplex analysis of proin-
flammatory cyto- and chemokines revealed that adriamy-
cin resulted in the increased levels of IL-1, IL-1, G-
CSF, and IL-8 (murine KC; Figure 7, A–D). Infusion of
EPCs to adriamycin-treated mice significantly reduced
plasma levels of IL-1 and -, and G-CSF, but increased
the level of KC, which is endowed with the ability to
mobilize stem cells. In addition, plasma levels of VEGF
were further increased by adoptive transfer of EPCs (Fig-
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Figure 2. Representative periodic acid-schiff-stained kidney sections and pathological scores. A: Normal
control (left); adriamycin-treated (middle); adriamycin followed by adoptive transfer of EPCs (right).
Upper panel, scale bar 	 100 m; lower panel, scale bar 	 50 m. See text for detailed description. B:
Semiquantitative scores of glomerular and tubulointerstitial injury. All kidneys were harvested on day 21
postadriamycin.
Figure 3. Dynamics of EPCs and HSCs in the kidney during AAN and after adoptive transfer of EPCs. A: The forward scatter (FSC)/side scatter (SSC) dot-plot was
used to gate kidney cells (upper left). Gated cells were displayed in the fluorescence FL1/FL2 (FITC on x axis/PE on y axis) dot-plot as unstained control (upper
right). Dot plot of anti–CD34-FITC versus anti–Flk-1–PE fluorescence (lower left). Dot plot of anti–c-kit–FITC versus anti–CD150-PE fluorescence (lower right).
B: Proportion of EPCs after administration of adriamycin. C: Proportion of HSCs after administration of adriamycin. *P  0.05 versus control and **P  0.05 versus
adriamycin, respectively; †P  0.05 versus Day 0 and ††P  0.05 Day 14, respectively (n 	 35). Black bars indicate control; gray bars, adriamycin; white bars,
adriamycin followed by adoptive transfer of EPCs.
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ure 7E). This was accompanied by the restoration of
microvascular density in the affected kidneys, as judged
by the analysis of CD31 and von Willebrand factor stain-
ing of the kidney cryosections (Figure 8A) and reduced
frequency of TUNEL-positive cells (Figure 8B). Based on
these findings it can be argued that changes in cyto- and
chemokine profile could have contributed to the thera-
peutic effect of adoptively transferred EPCs.
Recently, a novel pathway of cell-to-cell communica-
tion comprising the formation of TNT has been de-
scribed.11 TNT were shown to facilitate selective transfer
of organelles between distant cells. This mechanism ac-
counts for mitochondrial transfer between adult stem
cells and somatic cells rescuing their respiration.13 By all
existing accounts, this mechanism, although difficult to
demonstrate in vivo and therefore studied in cultured
cells, should play a significant role in intercellular com-
munication.14 Based on these studies we endeavored to
examine the possibility of existence of TNT mechanism in
endothelial cells subjected to adriamycin and presented
with EPCs. Subconfluent human umbilical vein endothe-
lial cells (HUVECs) were exposed to 1 mol/L adriamycin
for 1 hour, labeled with CFDA SE, and washed with fresh
culture medium. EPCs were labeled with Mitotracker,
Figure 4. Increased SDF-1 expression in the AAN kidneys and reduced clonogenic potential of
EPCs. A: Immunohistochemistry of SDF-1 in kidneys of control (left), adriamycin-treated (middle),
and adriamycin-treated mice adoptively transferred with EPCs (right). Magnification of images in
the upper and lower panel was 200 and 400, respectively. B: Clonogeneicity of EPCs obtained
from control and AAN mice. Upper panel: uptake of DiI-labeled acetylated low-density lipopro-
tein (left), and lectin binding (middle), and merged image (right). Middle panel: plated cells
formed clusters (left) and colonies were stained with CD31 (right). Lower panel: number of
colony-forming units (n 	 5).
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Figure 5. Adriamycin reduces viability and in-
duces senescence of EPCs. A: Rate of apoptotic
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harvested from the bone marrow of BALB/c and
C57/BL6 mice. X-bar showed each dosage of
adriamycin. Cells were harvested and stained 24
hours after adriamycin injection, then analyzed
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mice. B: Representative images and quantitative
summary of stress-induced premature senes-
cence of EPCs. Cells were subjected to adriamy-
cin for 2 hours and stained for senescence-asso-
ciated -galactosidase 5 days later. *P  0.05 vs. 0
mol/L. White bar: 0 mol/L, black bar 1 mol/L.
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washed, and presented to HUVEC cultures at one-tenth
of HUVEC density. (In companion experiments, the label-
ing with fluorophores was reversed: HUVECs were la-
beled with Mitotracker and EPCs with CFDA SE). As
illustrated in Figure 9A, multiple TNT were observed be-
tween EPCs and HUVECs, accompanied by the ex-
change of fluorophores. Notably, despite the scarcity of
EPCs, the number of HUVECs labeled with the fluoro-
phore loaded into EPCs much exceeded the number of
EPCs present in the co-culture (Figure 9B). This obser-
vation was further confirmed by FACS analysis (Figure
9C), which showed that 16.7  0.9% of HUVECs have
received the fluorophore from EPCs. Because it has been
demonstrated that adriamycin cytotoxicity is in part due
to developing mitochondrial dysfunction, we next ex-
amined the possibility that EPCs could renew mito-
chondrial pool in affected HUVECs. When EPCs were
labeled with MitoTracker, the proportion of adriamycin-
treated HUVECs acquiring this tracer reached 34.3 
1.2%, suggesting the transference coefficient from
EPCs to HUVECs of about 1:3. This process was by
and large unidirectional, because MitoTracker-labeled
HUVECs did not significantly enrich EPCs with this
tracer (not shown). These data strengthen the hypoth-
esis that a small number of EPCs could repetitively
engage a much larger population of adriamycin-
stressed HUVECs and potentially rescue them. If sim-
ilar processes occur in vivo, this mechanism could
Figure 6. Representative images and quantitative analysis of labeled EPCs engrafting the AAN kidneys. A: CFDA-labeled EPCs (left); CD31 immunohistochemistry
(middle); merged images (right). Upper panel: labeled transferred cells in the glomerulus; middle panel: afferent arteriole; lower panel: vasa recta. Scale
bar 	 50 m. B: The approximate number of EPCs engrafting the kidney in AAN was quantified by integrating the number of cells per section (10 m) to the
entire kidney volume. See text for the detailed description. *P  0.05 versus controlEPC and **P  0.05 versus day 14. Black bars indicate controlEPC; white
bars, adriamycinEPC.
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adriamycin in combination with the adoptive trans-
fer of EPCs or without it. A–D: Multiplex analysis
with Luminex IS100 (only parameters that reached
statistical significance are presented.) E: ELISA mea-
surement of VEGF concentration in the plasma.
Dotted horizontal lines represent respective con-
trols. *P  0.05 versus adriamycin.
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explain why a relatively modest number of engrafted
EPCs could improve renal function in AAN.
Discussion
The data presented herein provide a conceptual link
between the adriamycin-induced stem/progenitor cell
apoptotic death and development of their functional in-
competence that hampers the engraftment of the kidney
and the progressive nature of adriamycin-associated ne-
phropathy. Adoptive transfer of EPCs after adriamycin
injection significantly modifies the course of AAN: pro-
teinuria and plasma creatinine concentration are de-
creased and survival of animals improves. This functional
improvement is accompanied by the definitive signs of
morphological recovery and reduced levels of pro-inflam-
matory cytokines. Infused EPCs engrafting adriamycin
kidneys are detectable along the microvasculature and,
to a lesser degree, in the interstitium of the affected
kidneys and their adoptive transfer results in the numer-
ical increase in the population of HSCs and EPCs in the
kidneys. Collectively, these lines of investigation provide
strong circumstantial evidence favoring the hypothesis
that stem cell, and endothelial progenitor cell specifically,
injury by adriamycin is in part responsible for the regen-
erative failure and progressive nature of kidney disease.
Deleterious effects of adriamycin on glomerular endo-
thelial cells have been linked to the development of pro-
teinuria.15 Vascular dysfunction manifesting in blunted
responses to acetylcholine was also demonstrated in in
vitro studies of isolated thoracic aorta obtained from ad-
riamycin-injected rats,16 arguing in favor of the develop-
ing endothelial dysfunction. Previous studies of adriamy-
cin nephropathy showed that bone marrow–derived cells
engrafted the kidneys, and transdifferentiated into en-
dothelial cells and myofibroblasts, which co-expressed
endothelial markers suggestive of endothelial-mesen-
chymal transformation.17 Yet other investigations, al-
beit in ischemic kidneys, failed to detect any significant
contribution of bone marrow–derived cells to kidney
repair.18,19
Stressor-induced mobilization of stem cells is com-
mon. The surge in stem cells is usually, but not always,
associated with regenerative potential. EPCs have been
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Figure 8. EPC treatment restores microvascular
density and reduces the frequency of apoptosis
in AAN kidneys. A: Representative images of
kidney sections stained for CD31. Upper panel:
glomeruli; lower panel: tubulointerstitium. Con-
trol, left; adriamycin, middle; and adriamycin
followed by adoptive transfer of EPCs, right.
Graphs summarize capillary density in each
group. Image analysis was performed using Na-
tional Institutes of Health Image J software. The
procedure included threshold image intensity
adjustment that enabled identification of micro-
vasculature and quantification of pixels. *P 
0.05 versus control and **P  0.05 versus adria-
mycin. Scale bar 	 50 m. B: Representative
images of the TUNEL staining of kidney sections.
Upper panel: TUNEL-positive cells; lower panel:
merged image of nuclear staining with DAPI.
Control, left; adriamycin, middle; and adriamy-
cin followed by adoptive transfer of EPCs, right.
TUNEL-positive cells were observed mainly in
the outer medulla. Bar diagram summarizes the
frequency of TUNEL-positive cells. *P  0.05
versus adriamycin. Scale bar 	 50 m.
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shown to participate in regenerative processes. Transplan-
tation of EPCs augments neovascularization of ischemic/
infarcted myocardium, ischemic limbs, or brain.20,21 EPCs
may play a critical role in the maintenance of integrity of
vascular endothelium and in its repair after injury or in-
flammation.22 EPCs are subjected to various stressors,
similar to all somatic cells, which could impair their com-
petence.23 Hyperglycemia has been reported to reduce
survival and impair function of circulating EPCs.24 There
is emerging evidence that senescence may serve as an
Figure 9. Formation of TNT between intact EPCs and adriamycin-treated HUVECs resulting in mitochondrial exchange. A: A gallery of representative bright-field
(left) and merged fluorescence images (middle) and merged fluorescence and bright-field images (right) demonstrating TNT after 24 hours in coculture of
CDFA-labeled HUVECs (green fluorescence) and Mitotracker-labeled EPCs (red fluorescence). Black and white arrows show TNT and mitochondrial particles,
respectively. Bar 	 50 m. The bottom panel shows magnified images of the boxed region above. B: Exchange rate of Mitotracker (red fluorescence) quantified
with fluorescence microscopy. C: Exchanged rate of Mitotracker analyzed by FACS analysis. Dot plot illustrating separate HUVEC staining with CFDA (upper left),
EPC staining with Mitotracker (upper right), and after 24 hours in coculture (lower; FL1/FL2: green fluorescence, x axis/red fluorescence, y axis). Right panel:
bar diagram summarizing results of FACS analysis of double-stained (denoting that exchange occurred) HUVECs under control conditions and after adriamycin
treatment. *P  0.05 versus control.
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important mechanism mediating EPC dysfunction. De-
creased numbers and increased proportion of senescent
EPCs has been reported in patients with preeclampsia or
hypertension.24 Angiotensin II can induce EPC senes-
cence through the induction of oxidative stress and influ-
ence telomerase activity.25 Oxidized low-density lipoprotein
induces EPC senescence and dysfunction.26 In addi-
tion, EPC dysfunction has been documented in type I
and II diabetes, coronary artery disease, atherosclero-
sis, vasculitis with kidney involvement, and end-stage
renal disease.27–31
In this particular situation, AAN, the surge in renal
EPCs is either short-lived or decapitated. One of the main
reasons for that is reduced viability of endogenous EPCs,
their premature senescence and functional incompe-
tence, as judged by the higher frequency of apoptosis,
staining for senescence-associated -galactosidase and
reduced clonogenic potential. The fact that exogenous
intact EPCs improve structural and functional conse-
quences of adriamycin administration not only further
supports the role of these cells in kidney regeneration,
but also argues in favor of EPC competence as the nec-
essary prerequisite in accomplishing regenerative func-
tions. Because of the highly heterogeneous population of
HSCs and the ability of the monocytic cells to differentiate
toward endothelial lineage, it is much more challenging to
derive meaningful conclusions from the observed surge
in HSCs after EPC transplantation.
Although these studies did not intend to directly ad-
dress the mechanistic aspect(s) of EPC-mediated regen-
eration in adriamycin nephropathy, several assumptions
can be offered based on the sites of engraftment, results
of cyto- and chemokine analyses, VEGF levels and vas-
cular density in the kidneys, and in vitro findings of tunneling
nanotubes between EPCs and HUVECs. Morphological
analysis showed structural improvement of adriamycin
nephropathy when EPCs were adoptively transferred.
This was also associated with the elevation of plasma
VEGF levels and improvement in microvascular density.
Adoptive transfer of EPCs was also associated with the
reduction in plasma levels of IL-1 and -, potent pro-
inflammatory cytokines, and concomitant reduction of the
frequency of apoptosis. Elevation in plasma KC levels
after adoptive transfer of EPCs may be of interest as it has
not only pro-inflammatory effects but is also capable of
mobilizing stem cells and exerting paracrine mitogenic
effect, thus potentially explaining the surge in HSCs after
EPC infusion.32,33
Adriamycin toxicity has been ascribed in part to the
mitochondrial dysfunction because of the production of
reactive oxygen species.34,35 In this vein, a newly de-
scribed formation of tunneling nanotubes is of special
interest. Nanotubes were readily formed between EPCs
and cultured mature endothelial cells. Fluorophore label-
ing of the mitochondrial compartment in each cell type
showed exchange of mitochondria, which occurred pre-
dominantly in the direction from the intact EPCs to the
affected HUVECs. This process resulted in the much
larger population of HUVECs subjected to nanotube ex-
change than the actual number of EPCs, indicating that a
single EPC could provide organellar exchange to multiple
mature adriamycin-injured cells through repeated rounds
of tunneling nanotube exchange. The transference num-
ber in this case was approximately one EPC to three
HUVECs.
In conclusion, AAN is associated with development
of EPC apoptosis and premature senescence leading
to poor engraftment of the kidney, whereas adoptive
transfer of intact EPCs at the onset of AAN blunts its
morphological and functional manifestations through
direct engraftment, paracrine signaling and, probably,
via a TNT-mediated mitochondrial transfer.
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